102 related articles for article (PubMed ID: 26967161)
1. A Lymph Node Staging System for Gastric Cancer: A Hybrid Type Based on Topographic and Numeric Systems.
Choi YY; An JY; Katai H; Seto Y; Fukagawa T; Okumura Y; Kim DW; Kim HI; Cheong JH; Hyung WJ; Noh SH
PLoS One; 2016; 11(3):e0149555. PubMed ID: 26967161
[TBL] [Abstract][Full Text] [Related]
2. Challenging the Dogma: Stage migration or negative lymph nodes, which of them is the main player on gastric cancer prognosis?
Costa PMD; Antunes C; Lages P; Rodrigues J; Peyroteo M; Onofre S; Lara Santos L
Eur J Surg Oncol; 2024 Jun; 50(6):108318. PubMed ID: 38626587
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of the number of resected and negative lymph nodes in Spanish patients with gastric cancer.
Díaz Del Arco C; Ortega Medina L; Estrada Muñoz L; Molina Roldán E; García Gómez de Las Heras S; Fernández Aceñero MJ
Ann Diagn Pathol; 2023 Dec; 67():152209. PubMed ID: 37689040
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of perigastric tumor deposits in patients with primary gastric cancer.
Anup S; Lu J; Zheng CH; Li P; Xie JW; Wang JB; Lin JX; Chen QY; Cao LL; Lin M; Yu Q; Yang YH; Huang CM
BMC Surg; 2017 Jul; 17(1):84. PubMed ID: 28724367
[TBL] [Abstract][Full Text] [Related]
5. Essential TNM: a registry tool to reduce gaps in cancer staging information.
Piñeros M; Parkin DM; Ward K; Chokunonga E; Ervik M; Farrugia H; Gospodarowicz M; O'Sullivan B; Soerjomataram I; Swaminathan R; Znaor A; Bray F; Brierley J
Lancet Oncol; 2019 Feb; 20(2):e103-e111. PubMed ID: 30712797
[TBL] [Abstract][Full Text] [Related]
6. On an ensemble algorithm for clustering cancer patient data.
Qi R; Wu D; Sheng L; Henson D; Schwartz A; Xu E; Xing K; Chen D
BMC Syst Biol; 2013; 7 Suppl 4(Suppl 4):S9. PubMed ID: 24565417
[TBL] [Abstract][Full Text] [Related]
7. Lymph Node Ratio System for N Staging of Gastric Cancer: Challenging for Universal Application But Useful for the Prognostic Prediction of Individual Patients.
Kong SH
J Gastric Cancer; 2021 Mar; 21(1):1-3. PubMed ID: 33854808
[No Abstract] [Full Text] [Related]
8. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant nab-paclitaxel in the treatment of breast cancer.
Ueno NT; Mamounas EP
Breast Cancer Res Treat; 2016 Apr; 156(3):427-440. PubMed ID: 27072366
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Oki E; Murata A; Yoshida K; Maeda K; Ikejiri K; Munemoto Y; Sasaki K; Matsuda C; Kotake M; Suenaga T; Matsuda H; Emi Y; Kakeji Y; Baba H; Hamada C; Saji S; Maehara Y
Ann Oncol; 2016 Jul; 27(7):1266-72. PubMed ID: 27056996
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
Zhou J; Zhao R; Wen F; Zhang P; Wu Y; Tang R; Chen H; Zhang J; Li Q
Tumori; 2016 Jun; 2016(3):294-300. PubMed ID: 27056335
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma.
Scheithauer W; Kornek G; Prager G; Stranzl N; Laengle F; Schindl M; Friedl J; Klech J; Roethlin S; Zielinski C
J Gastrointest Oncol; 2016 Apr; 7(2):234-8. PubMed ID: 27034791
[TBL] [Abstract][Full Text] [Related]
14. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.
Suenaga M; Yamada S; Fujii T; Tanaka C; Kanda M; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
J Surg Oncol; 2016 Mar; 113(4):413-9. PubMed ID: 27100026
[TBL] [Abstract][Full Text] [Related]
15. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.
Tehfe M; Dowden S; Kennecke H; El-Maraghi R; Lesperance B; Couture F; Letourneau R; Liu H; Romano A
Adv Ther; 2016 May; 33(5):747-59. PubMed ID: 27085323
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).
Mizusawa J; Morizane C; Okusaka T; Katayama H; Ishii H; Fukuda H; Furuse J;
Jpn J Clin Oncol; 2016 Apr; 46(4):385-8. PubMed ID: 27025903
[TBL] [Abstract][Full Text] [Related]
17. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
Arita S; Shirakawa T; Matsushita Y; Shimokawa HK; Hirano G; Makiyama A; Shibata Y; Tamura S; Esaki T; Mitsugi K; Ariyama H; Kusaba H; Akashi K; Baba E
Anticancer Res; 2016 Apr; 36(4):1959-66. PubMed ID: 27069187
[TBL] [Abstract][Full Text] [Related]
19. Refining gastric cancer staging: examining the interplay between number and anatomical location of metastatic lymph nodes - a retrospective multi-institutional study.
Jeon CH; Park KB; Lee H; Kim DJ; Seo HS; Lee J; Jun KH; Kim JJ; Lee HH
BMC Cancer; 2023 Dec; 23(1):1192. PubMed ID: 38053052
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
